Showing results (1-10 of 527) with videos related to

Sort By:
Pageof 53
The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|October 19, 2021
Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug AdministrationAlexander C Egilman, Amy Kapczynski, Margaret E McCarthy, et al.
Research Integrity and Peer Review|December 24, 2019
Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017Alexander C Egilman, Joshua D Wallach, Christopher J Morten, et al.
JAMA Internal Medicine|October 29, 2019
Confidentiality Orders and Public Interest in Drug and Medical Device LitigationAlexander C Egilman, Aaron S Kesselheim, Harlan M Krumholz, et al.
JAMA Health Forum|August 17, 2022
Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017Joshua J Skydel, Alexander C Egilman, Joshua D Wallach, et al.
Health Affairs Scholar|November 17, 2025
Flexibility over rigor: stakeholder acceptance of the limitations of confirmatory studies following accelerated approvalHolly Fernandez Lynch, Sejin Lee, Matthew Herder, et al.
Research Integrity and Peer Review|February 17, 2018
Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiencesJoshua D Wallach, Alexander C Egilman, Anand D Gopal, et al.
JAMA Network Open|May 6, 2021
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic ReviewAaron S Long, Audrey D Zhang, Caitlin E Meyer, et al.
BMC Medical Research Methodology|March 16, 2020
Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart diseaseJoshua D Wallach, Stylianos Serghiou, Lingzhi Chu, et al.
JAMA Health Forum|June 9, 2023
Extending the US Food and Drug Administration's Postmarket AuthoritiesHolly Fernandez Lynch, Rachel E Sachs, Sejin Lee, et al.
BMJ (Clinical Research Ed.)|May 26, 2018
Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysisJoshua D Wallach, Alexander C Egilman, Sanket S Dhruva, et al.
Pageof 53